Yichen Yan
130 Dong An Road
Xuhui, 200032, China
Xuhui, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation.
Journal: Annals of hematology
Published: January 28, 2026
USP1-TRAF2 axis-regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 25, 2025
Elevated FGR protein expression identifies a high-risk subset of diffuse large B-cell lymphoma and a potential therapeutic target.
Journal: Frontiers in oncology
Published: August 19, 2025
Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV.
Journal: Biochemical and biophysical research communications
Published: August 12, 2024
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.
Journal: International journal of hematology
Published: January 27, 2024
A Regulatory Loop Involving miR-200c and NF-κB Modulates Mortalin Expression and Increases Cisplatin Sensitivity in an Ovarian Cancer Cell Line Model.
Journal: International journal of molecular sciences
Published: October 12, 2022
Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage.
Journal: Annals of translational medicine
Published: March 29, 2022
MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma.
Journal: Cancer letters
Published: February 01, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026